[Vic-]trastuzumab duocarmazine shows improved PFS in pre-treated HER2+ locally advanced or metastatic breast cancer

Share :
Published: 24 Sep 2021
Views: 1503
Dr Cristina Saura - Vall d’Hebron University Hospital, Barcelona, Spain

Dr Cristina Saura speaks to ecancer in an online interview as part of the ESMO 2021 meeting about the primary outcomes of the TULIP trial.

She explains that the trial compared [vic-]trastuzumab duocarmazine to physician’s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer.

Dr Saura reports that this treatment showed improvement in progression-free survival over physician’s choice treatment, and discusses the adverse events experienced.

Read more about the study here.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.